Francisco J. Fanjul

University Of The Balearic Islands
Palma, PM, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Implementing Indicator Condition-Guided HIV Screening Alerts in the Emergency Department: Lessons Learned from a Case Study.

Implementing Indicator Condition-Guided HIV Screening Alerts in the Emergency Department: Lessons Learned from a Case Study.

Journal: Inquiry : a journal of medical care organization, provision and financing

Published: July 24, 2026

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Journal: HIV medicine

Published: November 19, 2025

The Validation of Mortality Risk Indexes for Predicting Long-Term Outcomes in People Living with HIV in a Spanish Cohort (eVIHa).

The Validation of Mortality Risk Indexes for Predicting Long-Term Outcomes in People Living with HIV in a Spanish Cohort (eVIHa).

Journal: Journal of clinical medicine

Published: October 16, 2025

HIV Therapy: The Latest Developments in Antiviral Drugs-A Scoping Review.

HIV Therapy: The Latest Developments in Antiviral Drugs-A Scoping Review.

Journal: Biomedicines

Published: September 16, 2025

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Journal: HIV medicine

Published: July 28, 2025

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Journal: AIDS (London, England)

Published: July 02, 2025

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

Journal: AIDS (London, England)

Published: July 02, 2025

Association Between Excessive Alcohol Consumption When Starting Antiretroviral Therapy and Long-term Mortality in People Living With HIV.

Association Between Excessive Alcohol Consumption When Starting Antiretroviral Therapy and Long-term Mortality in People Living With HIV.

Journal: Journal of addiction medicine

Published: June 06, 2025

Understanding the Interaction Between Premature Ageing in HIV and COPD Using Epigenetic Clocks: A Case-Control Study Protocol.

Understanding the Interaction Between Premature Ageing in HIV and COPD Using Epigenetic Clocks: A Case-Control Study Protocol.

Journal: Open respiratory archives

Published: April 22, 2025

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

Journal: The lancet. HIV

Published: February 18, 2025

Showing 1-12 of 34

Last Updated: 09/26/2026